Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis.
Saved in:
| Title: | Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. |
|---|---|
| Authors: | Hayashi H; Department of Medical Oncology, Kindai University Faculty of Medicine, and Kindai Hospital Global Research Alliance Center (KHGRAC), Sakai, Osaka, Japan., Cho BC; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea., Kim YJ; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea., Lee SH; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea., Danchaivijitr P; Division of Medical Oncology, Department of Medicine, Siriraj Hospital Faculty of Medicine, Mahidol University Bangkok Noi Campus, Bangkok, Thailand., Alip A; Clinical Oncology Department, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia., Xiong H; Department of Medical Oncology, Huizhou Municipal Central Hospital of Guangdong Province, Huizhou, China., How SH; Department of Internal Medicine, Division of Respiratory Medicine, International Islamic University Malaysia, Pahang, Malaysia., Chang GC; School of Medicine and Institute of Medicine, Chung Shan Medical University and Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan., Yang JC; National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan., Yamanaka Y; Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan., Nahit Şendur MA; Department of Medical Oncology, Ankara Bilkent City Hospital and Ankara Yıldırım Beyazıt University, Ankara, Turkey., Prabhash K; Department of Medical Oncology, Division of Adult Solid Tumor Oncology, Tata Memorial Hospital, Mumbai, India., Azuma K; Kurume University School of Medicine, Kurume, Japan., Akawung A; Johnson & Johnson, Chestermere, AB, Canada., Fennema E; Johnson & Johnson, San Diego, CA, USA., Tang X; Johnson & Johnson, Shanghai, China., Shah S; Johnson & Johnson, Spring House, PA, USA., Sethi S; Johnson & Johnson, Spring House, PA, USA., Lu S; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shunlu@sjtu.edu.cn. |
| Source: | Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2026 Apr; Vol. 214, pp. 109305. Date of Electronic Publication: 2026 Feb 04. |
| Publication Type: | Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 41689889 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Hayashi+H%22">Hayashi H</searchLink>; Department of Medical Oncology, Kindai University Faculty of Medicine, and Kindai Hospital Global Research Alliance Center (KHGRAC), Sakai, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Cho+BC%22">Cho BC</searchLink>; Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Kim+YJ%22">Kim YJ</searchLink>; Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.<br /><searchLink fieldCode="AU" term="%22Lee+SH%22">Lee SH</searchLink>; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Danchaivijitr+P%22">Danchaivijitr P</searchLink>; Division of Medical Oncology, Department of Medicine, Siriraj Hospital Faculty of Medicine, Mahidol University Bangkok Noi Campus, Bangkok, Thailand.<br /><searchLink fieldCode="AU" term="%22Alip+A%22">Alip A</searchLink>; Clinical Oncology Department, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.<br /><searchLink fieldCode="AU" term="%22Xiong+H%22">Xiong H</searchLink>; Department of Medical Oncology, Huizhou Municipal Central Hospital of Guangdong Province, Huizhou, China.<br /><searchLink fieldCode="AU" term="%22How+SH%22">How SH</searchLink>; Department of Internal Medicine, Division of Respiratory Medicine, International Islamic University Malaysia, Pahang, Malaysia.<br /><searchLink fieldCode="AU" term="%22Chang+GC%22">Chang GC</searchLink>; School of Medicine and Institute of Medicine, Chung Shan Medical University and Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung, Taiwan.<br /><searchLink fieldCode="AU" term="%22Yang+JC%22">Yang JC</searchLink>; National Taiwan University Cancer Center, National Taiwan University Hospital, Taipei, Taiwan.<br /><searchLink fieldCode="AU" term="%22Yamanaka+Y%22">Yamanaka Y</searchLink>; Department of Thoracic Oncology, Kansai Medical University Hospital, Hirakata, Japan.<br /><searchLink fieldCode="AU" term="%22Nahit+Şendur+MA%22">Nahit Şendur MA</searchLink>; Department of Medical Oncology, Ankara Bilkent City Hospital and Ankara Yıldırım Beyazıt University, Ankara, Turkey.<br /><searchLink fieldCode="AU" term="%22Prabhash+K%22">Prabhash K</searchLink>; Department of Medical Oncology, Division of Adult Solid Tumor Oncology, Tata Memorial Hospital, Mumbai, India.<br /><searchLink fieldCode="AU" term="%22Azuma+K%22">Azuma K</searchLink>; Kurume University School of Medicine, Kurume, Japan.<br /><searchLink fieldCode="AU" term="%22Akawung+A%22">Akawung A</searchLink>; Johnson & Johnson, Chestermere, AB, Canada.<br /><searchLink fieldCode="AU" term="%22Fennema+E%22">Fennema E</searchLink>; Johnson & Johnson, San Diego, CA, USA.<br /><searchLink fieldCode="AU" term="%22Tang+X%22">Tang X</searchLink>; Johnson & Johnson, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Shah+S%22">Shah S</searchLink>; Johnson & Johnson, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Sethi+S%22">Sethi S</searchLink>; Johnson & Johnson, Spring House, PA, USA.<br /><searchLink fieldCode="AU" term="%22Lu+S%22">Lu S</searchLink>; Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China. Electronic address: shunlu@sjtu.edu.cn. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228800805%22">Lung cancer (Amsterdam, Netherlands)</searchLink> [Lung Cancer] 2026 Apr; Vol. 214, pp. 109305. <i>Date of Electronic Publication: </i>2026 Feb 04. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Randomized Controlled Trial – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Scientific+Publishers%22">Elsevier Scientific Publishers </searchLink><i>Country of Publication: </i>Ireland <i>NLM ID: </i>8800805 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1872-8332 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201695002%22">01695002 </searchLink><i>NLM ISO Abbreviation: </i>Lung Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41689889 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.lungcan.2026.109305 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 109305 Titles: – TitleFull: Overall survival for amivantamab plus lazertinib versus osimertinib as first-line treatment in Asian participants with EGFR-mutant advanced NSCLC: A MARIPOSA subset analysis. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Hayashi H – PersonEntity: Name: NameFull: Cho BC – PersonEntity: Name: NameFull: Kim YJ – PersonEntity: Name: NameFull: Lee SH – PersonEntity: Name: NameFull: Danchaivijitr P – PersonEntity: Name: NameFull: Alip A – PersonEntity: Name: NameFull: Xiong H – PersonEntity: Name: NameFull: How SH – PersonEntity: Name: NameFull: Chang GC – PersonEntity: Name: NameFull: Yang JC – PersonEntity: Name: NameFull: Yamanaka Y – PersonEntity: Name: NameFull: Nahit Şendur MA – PersonEntity: Name: NameFull: Prabhash K – PersonEntity: Name: NameFull: Azuma K – PersonEntity: Name: NameFull: Akawung A – PersonEntity: Name: NameFull: Fennema E – PersonEntity: Name: NameFull: Tang X – PersonEntity: Name: NameFull: Shah S – PersonEntity: Name: NameFull: Sethi S – PersonEntity: Name: NameFull: Lu S IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2026 Apr Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1872-8332 Numbering: – Type: volume Value: 214 Titles: – TitleFull: Lung cancer (Amsterdam, Netherlands) Type: main |
| ResultId | 1 |
